Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBTH17 Cells May Serve as Biomarker in Metastatic Melanoma. By Morgan Bayer. September 28th 2024. TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
DREAMM-8 Trial Demonstrates Benefits of Belantamab Mafodotin
WEB1 day ago · Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial. Meletios Dimopoulous, MD. Belantamab mafodotin-blmf (Blenrep) in addition to pomalidomide (Pomalyst) and ...
FDA Approves Perioperative Nivolumab in Resectable NSCLC
WEB14 hours ago · The FDA has approved neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab in patients with operable stage IIA to IIIB NSCLC, as supported by findings from the phase 3 CheckMate 77T trial. 1. Updated data were presented at the 2024 ESMO Congress, showing that perioperative nivolumab led to …
LUNG CANCER - Targeted Oncology
WEBZipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC. Kristie L. Kahl. September 14th 2024. Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Bladder Cancer - Targeted Oncology
WEBFDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ. Jordyn Sava. April 22nd 2024. Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Neoadjuvant/Adjuvant Durvalumab Scores FDA Approval in …
WEBAug 15, 2024 · The FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. This approval is supported by the phase 3 AEGEAN trial (NCT03800134). Durvalumab led to notable improvements in event-free survival (EFS) vs placebo.
News - Targeted Oncology
WEBFDA Grants FTD to EO-3021 in Advanced Gastric and GEJ Cancers Expressing Claudin 18.2. Jordyn Sava. September 23rd 2024. The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal junction cancers expressing Claudin 18.2, which have progressed after prior therapy.
IMMUNOTHERAPY - Targeted Oncology
WEBJuly 26th 2024. SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy. FDA ODAC Votes Unanimously to Mandate Phase Assessments in NSCLC Perioperative Regimens. By Jordyn Sava. July 25th 2024.
The Targeted Pulse: FDA’s ODAC Mandates New Phase
WEBAug 4, 2024 · The FDA’s ODAC mandates phase assessments for NSCLC trials, dendritic cell immunotherapy shows improved survival in pancreatic cancer, and a new blood test for colorectal cancer receives FDA approval. In addition, pembrolizumab plus neoadjuvant chemo proves effective in unresectable HGSC and THIO-cemiplimab combo shows lower toxicity in advanced NSCLC.
The Targeted Pulse: New Pancreatic Cancer Therapy ... - Targeted …
WEBFeb 19, 2024 · The liposomal irinotecan (Onivyde), 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) combination received FDA approval for patients with metastatic pancreatic cancer in the first-line setting. The combination showed improved overall survival (OS) and progression-free survival (PFS) compared with nab-paclitaxel (Abraxane) in the ...